Open Heart

MAY 7, 2024

Background The treatment of pulmonary hypertension (PH) has improved rapidly in recent decades. There is increasing evidence to support the role of early intervention and treatment in affecting clinical outcomes in PH. Methods Patients were compared before and after treatment escalation.

Heart Monitor 52

Heart Monitor Pulmonary Hypertension Angioplasty 52

Open Heart

JUNE 8, 2022

Objective Pulmonary arterial hypertension (PAH), caused by pulmonary artery remodelling and increased pulmonary vascular resistance (PVR) due to an unknown mechanism, is an intractable disease with a poor prognosis. The primary outcome was death or lung transplantation.

Pulmonary 52

Pulmonary Hypertension Transplant Risk Factors 52

Journal of the American Heart Association

DECEMBER 1, 2023

BackgroundThe modified Blalock‐Taussig‐Thomas shunt is the gold standard palliation for securing pulmonary blood flow in infants with ductal‐dependent pulmonary blood flow. Intervention was not significantly associated with odds of 30‐day transplant‐free survival (OR,1.18 [95% CI, 0.70–1.99])

Pediatrics 40

Pediatrics Pulmonary Stents Stent 40

DAIC

JUNE 24, 2024

Food and Drug Administration ( FDA ) of the company's Cordella Pulmonary Artery (PA) Sensor System for the treatment of New York Heart Failure (NYHA) class III heart failure patients. PROACTIVE-HF demonstrated that with Cordella clinicians achieved more optimal and timely dosing of key HF medications, significantly improving outcomes.

Heart Failure 109

Heart Failure Reimbursement Heart Transplant Pulmonary 109

Open Heart

NOVEMBER 25, 2022

Cox models were created to investigate if UA was a significant predictor of adverse outcome where log1.1(UA) UA) was used to estimate the effect on outcome associated with a 10% increase in UA levels. Median UA was 0.48 (0.39–0.61) mmol/L.

Heart Failure 52

Heart Failure Outcomes Heart Transplant Artificial Heart 52

Frontiers in Cardiovascular Medicine

MARCH 3, 2024

Background Objective tools to define the optimal time for referral for advanced therapies and to help guide escalation and de-escalation of support can improve management decisions and outcomes for patients with advanced heart failure. Results Approximately 1010 discrete heart failure scenarios were modeled.

Heart Failure 85

Heart Failure Cardiogenic Shock Physiology Transplant 85

DAIC

MARCH 13, 2024

To my knowledge, no therapy has been proven to reduce mortality in these patients, and CardiAMP Heart Failure II has great potential to achieve this outcome by confirming our CardiAMP Heart Failure Trial results.” Getty Images milla1cf Wed, 03/13/2024 - 16:49 March 13, 2024 — BioCardia, Inc. , said Peter Altman , PhD.,

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111